The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion

被引:11
作者
Caceda, Ricardo [1 ]
Binder, Elisabeth B. [1 ]
Kinkead, Becky [1 ]
Nemeroff, Charles B. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA
基金
美国国家卫生研究院;
关键词
Prepulse inhibition; Locomotion; D-amphetamine; Apomorphine; Dizocilpine; c-fos; Neurotensin; FOS MESSENGER-RNA; VENTRAL TEGMENTAL AREA; NUCLEUS-ACCUMBENS NEURONS; ANTAGONIST SR 142948A; IMMEDIATE-EARLY GENES; C-FOS; RECEPTOR ANTAGONIST; BEHAVIORAL SENSITIZATION; DOPAMINE D-1; COLOCALIZED TRANSMITTERS;
D O I
10.1016/j.schres.2011.10.013
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The neuropeptide neurotensin (NT) is closely associated with dopaminergic and glutamatergic systems in the rat brain. Central injection of NT into the nucleus accumbens (NAcc) or peripheral administration of NT receptor agonists, reduces many of the behavioral effects of psychostimulants. However, the role of endogenous NT in the behavioral effects of psychostimulants (e.g. DA agonists and NMDA receptor antagonists) remains unclear. Using a NTR antagonist, SR142948A, the current studies were designed to examine the role of endogenous NT in DA receptor agonist-and NMDA receptor antagonist-induced disruption of prepulse inhibition of the acoustic startle response (PPI), locomotor hyperactivity and brain-region specific c-fos mRNA expression. Adult male rats received a single i.p. injection of SR142948A or vehicle followed by D-amphetamine, apomorphine or dizocilpine challenge. SR142948A had no effect on baseline PPI, but dose-dependently attenuated D-amphetamine-and dizocilpine-induced PPI disruption and enhanced apomorphine-induced PPI disruption. SR142948A did not significantly affect either baseline locomotor activity or stimulant-induced hyperlocomotion. Systemic SR142948A administration prevented c-fos mRNA induction in mesolimbic terminal fields (prefrontal cortex, lateral septum, NAcc, ventral subiculum) induced by all three psychostimulants implicating the VTA as the site for NTmodulation of stimulant-induced PPI disruption. Further characterization of the NT system may be valuable to find clinical useful compounds for schizophrenia and drug addiction. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:88 / 95
页数:8
相关论文
共 91 条
[1]   Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain [J].
Alonso, R ;
Gnanadicom, H ;
Fréchin, N ;
Fournier, M ;
Le Fur, G ;
Soubrié, P .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (03) :967-974
[2]   Amphetamine induces Fos-like immunoreactivity in the striatum of primates [J].
Asin, KE ;
Wirtshafter, D ;
Nikkel, A .
BRAIN RESEARCH, 1996, 719 (1-2) :138-142
[3]   Central neurotensin receptor activation produces differential behavioral responses in Fischer and Lewis rats [J].
Bauco, P ;
Rompré, PP .
PSYCHOPHARMACOLOGY, 2003, 168 (03) :253-261
[4]   EFFECTS OF DOPAMINE AUTORECEPTOR STIMULATION ON THE RELEASE OF COLOCALIZED TRANSMITTERS - INVIVO RELEASE OF DOPAMINE AND NEUROTENSIN FROM RAT PREFRONTAL CORTEX [J].
BEAN, AJ ;
DURING, MJ ;
ROTH, RH .
NEUROSCIENCE LETTERS, 1990, 108 (1-2) :143-148
[5]  
Betancur C, 1998, NEUROPSYCHOPHARMACOL, V19, P322, DOI 10.1038/sj.npp.1395212
[6]  
Beurrier C, 2002, J NEUROSCI, V22, P5817
[7]   Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs [J].
Binder, EB ;
Kinkead, B ;
Owens, MJ ;
Nemeroff, CB .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (12) :2200-2207
[8]  
Binder EB, 2001, PHARMACOL REV, V53, P453
[9]   Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating [J].
Binder, EB ;
Kinkead, B ;
Owens, MJ ;
Kilts, CD ;
Nemeroff, CB .
JOURNAL OF NEUROSCIENCE, 2001, 21 (02) :601-608
[10]   A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity [J].
Boules, M ;
Warrington, L ;
Fauq, A ;
McCormick, D ;
Richelson, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 426 (1-2) :73-76